Gallorini A, Plebani M, Pontisso P, Chemello L, Masiero M, Mantovani G, Alberti A
Istituto di Medicina Clinica, Università di Padova, Italy.
Liver. 1994 Oct;14(5):257-64. doi: 10.1111/j.1600-0676.1994.tb00085.x.
Hepatic fibrogenesis is a dynamic process which characterizes the course of chronic hepatitis. It has stimulated interest in the possible effect of interferon therapy on liver fibrosis. We have evaluated a panel of serum markers of fibrogenesis, namely N-terminal procollagen III peptide (PII-INP), C-terminal procollagen I peptide (PICP), laminin and hyaluronate in 35 patients with chronic hepatitis type C, before, during and after interferon treatment. Before treatment, PIIINP was elevated in 8.5%, 44% and 71% of patients with chronic persistent hepatitis, chronic active hepatitis and cirrhosis, respectively, while the corresponding figures for PICP were 0%, 50% and 46%, and for laminin 16.5%, 70% and 71%; hyaluronate was elevated in only five out of seven patients with cirrhosis. Patients with high PIIINP levels at presentation and a persistent response to treatment showed persistent normalization of this parameter, which was not observed in non-responders. In contrast, the other markers showed no significant correlation with interferon response. These results indicate that PIIINP correlates with interferon response in chronic hepatitis type C.
肝纤维化形成是一个动态过程，是慢性肝炎病程的特征。这激发了人们对干扰素治疗对肝纤维化可能产生的影响的兴趣。我们评估了一组肝纤维化血清标志物，即Ⅲ型前胶原氨基端肽（PII-INP）、Ⅰ型前胶原羧基端肽（PICP）、层粘连蛋白和透明质酸，对35例丙型慢性肝炎患者在干扰素治疗前、治疗期间和治疗后进行了检测。治疗前，慢性持续性肝炎、慢性活动性肝炎和肝硬化患者中PIIINP升高的比例分别为8.5%、44%和71%，而PICP的相应比例分别为0%、50%和46%，层粘连蛋白的相应比例分别为16.5%、70%和71%；仅7例肝硬化患者中有5例透明质酸升高。治疗开始时PIIINP水平高且对治疗持续有反应的患者，该参数持续正常化，而无反应者未观察到这种情况。相比之下，其他标志物与干扰素反应无显著相关性。这些结果表明，PIIINP与丙型慢性肝炎的干扰素反应相关。
